Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
qirong fuzheng mixture
- Development stage
- Phase 3
- Lead developer
- Shenzhen Third People's Hospital
- Administration
- Oral
01
Overview
Qirong Fuzheng Mixture is a Traditional Chinese Medicine (TCM) herbal formulation developed as an immunomodulatory therapy, particularly for patients with HIV/AIDS. The formulation typically contains extracts from *Astragalus membranaceus* (Huangqi) and *Cistanche deserticola* (Roucongrong), which are traditionally used to tonify "Qi" and "Yang" to strengthen the body's resistance (Fuzheng). In clinical settings, it is administered as an adjuvant to antiretroviral therapy (ART) to promote immune reconstitution, increase CD4+ T-lymphocyte counts, and improve the quality of life by reducing symptoms such as fatigue. The drug is currently being investigated in clinical trials sponsored by The Third People's Hospital of Shenzhen.
- Other names
- 芪茸扶正合剂Qirong Fuzheng Heji
Beyond the preview
Go deeper on qirong fuzheng mixture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on qirong fuzheng mixture.